Wat is de prijs voor Medigene AG (MDG1)

Het prijs van Medigene AG (MDG1) is $0.14942078

Wat is de marktkapitalisatie voor Medigene AG (MDG1)

Marktkapitalisatie voorMedigene AG (MDG1) is $3.86M

Medigene AG (MDG1) Aandelensplitsingen

Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
2024-08-29	1:2	x0.5	x0.125
2013-09-03	1:4	x0.25	x0.25

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

2024-08-29

1:2

x0.5

x0.125

2013-09-03

1:4

x0.25

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land